A
Alcista
Alcista · 25%ATRC
$43.30
Precio del escenario
$57.300
+0.435 (+0.76%)Al cierre
Loading chart…
- Máximo
- 57.890
- Apertura
- 56.130
- Precio medio ponderado por volumen
- 57.01
- Volumen
- 799.31K
- Capitalización
- 1.13B
- Mínimo
- 55.840
- Importe
- 45.57M
- EV/EBITDA, TTM
- 44.30
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Análisis de IA of AtriCure, Inc. (ATRC)
MantenerAtriCure Inc is currently priced at $55.81, which is close to its 52-week high of $56.02. The stock has shown a strong year-to-date increase of 42.12% and a one-year change of 56.77%. However, the forward P/E ratio is very high at 232.56, indicating that the stock might be overvalued. Additionally, recent insider selling raises some caution, although the insider retains a significant stake worth approximately $7.9 million. The mixed analyst ratings, with targets from $43 to $60, suggest uncertainty about future price movements, making it prudent to hold rather than buy at this price.
Recomendaciones de analistas (8)
-8.90% Potencial de caída
Comprar
7 Comprar
1 Mantener
0 Vender
Actual: 57.30
Mínimo
45.00
Promedio
52.20
Máximo
64.00
BTIG
Comprar
$63
2026-10-12
BTIG
2026-10-12
Precio objetivo
$63
Comprar
Freedom Capital
Mantener
$57
2026-10-02
Freedom Capital
2026-10-02
Precio objetivo
$57
Mantener
Piper Sandler
Sobreponderar
$60
2026-08-27
Piper Sandler
2026-08-27
Precio objetivo
$60
Sobreponderar
BTIG
Comprar
$55
2026-08-24
BTIG
2026-08-24
Precio objetivo
$55
Comprar
UBS
Comprar
$50
2026-07-28
UBS
2026-07-28
Precio objetivo
$50
Comprar
Métricas de valoración
El PER previsto actual de AtriCure, Inc. (ATRC) es 232.56, frente a su media de 5 años de 8.36.
Escenarios de precio de Alphio AI para ATRC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ATRC en cartera
Cronología de eventos
Noticias
7.509-24NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Positive Catalysts
7.509-15NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Clinical Results
5.009-13FoolAtriCure Executive Stock Sale Analysis
5.009-13NASDAQ.COMAtriCure Insider Sale Analysis: Implications and Insights
7.509-09NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Clinical Developments
Preguntas frecuentes sobre ATRC, respondidas por Alphio AI
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
AtriCure Inc is currently priced at $55.81, which is close to its 52-week high of $56.02. The stock has shown a strong year-to-date increase of 42.12% and a one-year change of 56.77%. However, the forward P/E ratio is very high at 232.56, indicating that the stock might be overvalued. Additionally, recent insider selling raises some caution, although the insider retains a significant stake worth approximately $7.9 million. The mixed analyst ratings, with targets from $43 to $60, suggest uncertainty about future price movements, making it prudent to hold rather than buy at this price.
8 analysts cover ATRC: 7 rate it Buy, 1 Hold and 0 Sell. The average price target is 52.20.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.